In conclusion, this retrospective study examining the impact of CLDN4 expression on long-term outcomes in triple-negative breast cancer patients from Isfahan, Iran, did not find a significant association between CLDN4 levels and five-year overall survival, metastasis, or recurrence rates. Here, CLDN4 is linked to triple-negative breast carcinoma.